Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53
Figure 3
Combination of BIBF1120 and paclitaxel produces a profound increase in the percentage of cells in G2/M. Cell cycle profiles of parental (a) and paclitaxel-resistant Hec50A (b) and Hec50E (c) cells after treatment with 1 μM BIBF1120, 14 nM paclitaxel, or the combination for 24 h. The percentage of cells in G2/M is indicated in each plot.
